PRA Health Sciences
PRA Health Sciences Announces The Center for Pediatric Clinical Development
"PRA has a strong background in conducting pediatric clinical trials," said Mark Sorrentino, Vice President, The Center for Pediatric Clinical Development. "We see this new center as an opportunity to establish PRA as the industry leader in pediatric drug development and bring innovation to pediatric clinical trial design and implementation."
PRA has conducted the pivotal and/or supportive trials to gain 12 FDA and/or international regulatory approvals for drugs used in treating pediatric patients across multiple therapeutic areas. The Center for Pediatric Clinical Development is supported by a cross-functional group of experts who will provide strategic pediatric product development consulting services as well as experienced technical and operational services.
"This pediatric collaboration team provides the foundation for The Center for Pediatric Clinical Development," added Sorrentino. "The team will provide pediatric expertise across functional areas into a single global resource to support all aspects of our clients' pediatric product development needs."
The team will help navigate the complexities of pediatric trials and brings a wealth of knowledge in understanding the diverse country-specific regulatory and legal challenges in the pediatric environment. One of the many benefits of the center will be a site network to accelerate patient recruitment, and improve patient engagement and retention.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 13,000 employees worldwide. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com .
INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications
EMAIL: email@example.com PHONE: +1 919.786.8463
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Venanpri Group23.3.2018 12:01 | pressemeddelelse
Agrisolutions Acquires Trinity
Crown Bioscience Inc.22.3.2018 14:45 | pressemeddelelse
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
SEMAFO Inc.22.3.2018 12:01 | pressemeddelelse
SEMAFO: Construction of Boungou Mine 87% Complete
3Gtms21.3.2018 15:02 | pressemeddelelse
3Gtms Positioned in the Niche Players Quadrant of the Gartner Magic Quadrant for Transportation Management Systems
Addivant21.3.2018 14:39 | pressemeddelelse
Addivant Announces Price Increases on Hindered Amine Light Stablizers
VistaJet Ltd21.3.2018 14:19 | pressemeddelelse
VistaJet Connects Customers and Their Passions With the Global British Polo Day Tour
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum